Ligand id: 6880

Name: daclizumab

Compound class Antibody
Approved drug? Yes (FDA FDA (1997), EMA (1999))
Withdrawn drug? Yes
International Nonproprietary Names
INN number INN
7164 daclizumab
L04AC01 | RO-24-7375 | Ro-247375 | Zenapax®
Database Links
Specialist databases
IMGT/mAb-DB 36
Other databases
GtoPdb PubChem SID 178103462
PubChem SID 178103462
Search PubMed clinical trials daclizumab
Search PubMed titles daclizumab
Search PubMed titles/abstracts daclizumab
Wikipedia Daclizumab
Daclizumab is a monoclonal antibody binding to the α subunit (CD25) of the high-affinity interleukin-2 receptor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

An advanced version of daclizumab, with identical primary sequence, but which is differentially gylcosylated, called daclizumab beta (BIIB019, DAC HYP) has been developed for subcutaneous administration. Daclizumab beta's alternate glycosylation pattern changes its binding to Fc receptors and reduces its propensity to induce complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).